Dr. Reddy's Laboratories is currently trading at Rs. 5271.15, up by 19.90 points or 0.38% from its previous closing of Rs. 5251.25 on the BSE.
The scrip opened at Rs. 5282.55 and has touched a high and low of Rs. 5305.00 and Rs. 5261.80 respectively. So far 31575 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 5514.65 on 21-Sep-2020 and a 52 week low of Rs. 3613.45 on 18-May-2020.
Last one week high and low of the scrip stood at Rs. 5398.00 and Rs. 5143.50 respectively. The current market cap of the company is Rs. 87662.37 crore.
The promoters holding in the company stood at 26.74%, while Institutions and Non-Institutions held 43.93% and 17.06% respectively.
Dr. Reddy's Laboratories and Apollo Hospitals have collaborated to initiate a COVID-19 vaccination programme with Sputnik V. The first phase of the programme will kick off with vaccinations in Hyderabad on May 17, 2021 and in Visakhapatnam on May 18, 2021 at Apollo facilities. The two entities were working to scale up the pilot and take the vaccine to other cities with an aim to inoculate as many Indians as possible.
Dr. Reddy's Laboratories is a multinational pharmaceutical company based in Hyderabad, Telangana in India. It manufactures and markets a wide range of pharmaceuticals in India and overseas.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1872.40 |
| Dr. Reddys Lab | 1279.70 |
| Cipla | 1304.70 |
| Zydus Lifesciences | 956.65 |
| Lupin | 2245.65 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: